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The emergence of KPC-2 producing K. pneumoniae in hospitalized patients at the intensive
care unit (ICU) of a teaching hospital located in the city of João Pessoa, Paraíba, Brazil, is
reported. Seven carbapenem-resistant K. pneumoniae recovered from different body sites of
infectionwere analyzed.Most isolates showedamultidrug-resistance phenotype. Genotypic
analysis demonstrated the presence of two genotypes, with the predominance of genotype
A, which belongs to ST 437. These isolates also carry the encoding genes of ﬁve other beta-eta-lactam resistance
odiﬁed Hodge test
arbapenem resistance
nterobacteriaceae
lactamases.
ceptibility testing was performed by the agar dilution method,
according to the Clinical and Laboratory Standards Institute’s
10
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDlebsiella pneumoniae carbapenemases (KPC)-producing Entero-
acteriaceae isolates have become a signiﬁcant problem
orldwide. KPC are enzymes that hydrolyze penicillins,
ephalosporins, monobactams, and carbapenems, and are
nhibited by clavulanic acid and tazobactan.1 Of notice, genes
ncoding KPC enzymes are frequently located on transferable
lasmids. KPC-producing clinical isolates have been associ-
ted with hospital outbreaks in the USA, Asia, Europe, South
orea, and Central and South America.2 In Brazil, KPC-2-
roducing isolates have been initially reported in the cities
f Recife, Rio de Janeiro, São Paulo, and Porto Alegre.3–9 In
his report, the emergence of KPC-producing-K. pneumoniae
KPC-KPN) clinical isolates recovered at the tertiary teaching
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88, Vila Clementino – São Paulo/SP, 04025-010, Brazil.
E-mail address: lorenafehlberg@gmail.com (L.C.C. Fehlberg).
413-8670 © 2012 Elsevier Editora Ltda.
ttp://dx.doi.org/10.1016/j.bjid.2012.07.001
Este é um artigo Open Access sob a licençaHospital Lauro Wanderley, located in João Pessoa, Paraíba,
Brazil is described.
In the period between 2009 and 2010, seven K. pneumoniae
isolates were collected from different body sites of infection
of ﬁve patients who were hospitalized at the intensive care
unit (ICU) of the Hospital Lauro Wanderley. Initially, these
isolates were identiﬁed as resistant to ertapenem by disc
diffusion method, and were referred to the Laboratório Alerta,
UNIFESP, São Paulo, Brazil for further characterization. Sus-iseases, Universidade Federal de São Paulo, Rua Leandro Dupret,
(CLSI) guidelines for amikacin, aztreonam, cefepime, cefox-
itin, ceftazidime, ceftriaxone, ciproﬂoxacin, ertapenem,
 de CC BY-NC-ND
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Table 1 – Clinical features of the patients who had K. pneumoniae KPC-2-producing isolates at Hospital University Lauro Wanderley, João Pessoa, Paraíba, Brazil.
Patient Isolate PFGE
pattern
ST Gender Age (y) Underlyning
disease
Primary
infection
Treatment Antimicrobial
resistant
MIC carbapenems
(CLSI 2010)*
Bacteria
isolation
(day/mo/yr)
Beta-
lactamases
ICU
admission
(day/mo/yr)
Death
(day/mo/yr)
IMI MEM
1 335 A1 437 F 52 Bowel
cancer
Blood-
stream
CS, MEM,
AMG
ERT, CAZ,
CRO, CFO,
CIP, ATM
1 (S) 1 (S) 20/02/2010 KPC-2; TEM-1;
OXA-1;
CTX-M-15;
SHV-11
19/02/2010 22/02/2010
2 336 A1 437 F 71 Diabetes Blood-
stream
CAZ, CLI,
CIP, MEM
ERT, CAZ,
CRO, CFO,
CIP, ATM
2 (I) 2 (I)
09/09/2009
pc
KPC-2; TEM-1;
OXA-1;
CTX-M-15;
SHV-11
03/09/2009 09/09/2009
339 A1 437 F 71 Diabetes Urinary
tract
ERT, IMI,
CAZ, CRO,
CFO CIP, ATM
16 (R) 0,5 (S)
3 337 B1 70 F 29 HIV Blood-
stream
CS, MEM,
AMG, FUN
ERT, CRO,
CIP, ATM
2 (I) 1 (S) 13/02/2009
KPC-2; SHV-27 21/02/2009 16/03/2009
338 B1 70 F 29 HIV Pneumonia ERT, CAZ,
CRO, CFO,
ATM, MEM,
IMI
8 (R) 64 (R) 20/02/2009
4 340 A1 437 M 65 Encepha-
lopaty
Blood-
stream
CS, MEM,
AMG, VAN
ERT, CAZ,
IMI, CRO,
CFO, CIP,
ATM
4 (R) 2 (I) 08/08/2009 KPC-2; TEM-1;
OXA-1;
CTX-M-15;
SHV-11
18/08/2009 25/10/2009
5 341 A1 437 F 52 Post
gastrectomy
Wound MEM ERT, CAZ,
IMI, CRO,
CFO, CIP,
ATM
4 (R) 1 (S) 17/08/2009 KPC-2; TEM-1;
OXA-1;
CTX-M-15;
SHV-11
12/08/2009 18/08/2009
AMG, aminoglycosides; ATM, aztreonam; CAZ, ceftazidime; CFO, cefoxitin; CIP, ciproﬂoxacin; CLI, clindamycin; CRO, ceftriaxone; CS, 3th and 4th cephalosporins; ERT, ertapenem; F, female; FUN,
antifungal; HIV, human immunodeﬁciency virus infection; I, susceptibility reduced; ICU, intensive care unit; IMI, imipenem; M, male; MEM, meropenem; R; resistant; S, susceptible; ST, sequence type;
VAN, vancomycin.
∗ MICs were determined by agar dilution.
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mipenem, meropenem, and piperacillin/tazobactam. Min-
mum inhibitory concentrations (MICs) for tigecycline and
olymyxin B were determined by Etest (bioMérieux – Marcy
’Etóile, France) and interpreted according to the Euro-
ean Committee on Antimicrobial Susceptibility Testing’s
EUCAST) guidelines.11 The Modiﬁed Hodge Test (MHT) with
rtapenem disk (10g) was used for phenotypic detection
f carbapenemase activity.12 Speciﬁc primers were used
nder standard polymerase chain reaction (PCR) condi-
ions to detect the genes blaKPC, blaGES, blaCTX-M, blaSHV,
laTEM, blaOXA-1, blaOXA-2, blaOXA-10, blaOXA-18/45, and blaOXA-161,
ollowed by DNA sequencing (ABI sequencer - Applied Biosys-
ems, Foster City, CA). Clonal relatedness among isolates
as examined by pulsed ﬁeld gel electrophoresis (PFGE)
sing SpeI (New England, Beverly, MA). The band patterns
ere analyzed by visual interpretation, applying the criteria
stablished by Tenover et al.13 In addition, the PFGE patterns
ere analyzed using Bionumerics version 5.10 (Applied
aths, Sint-Martens – Latem, Belgium) for comparison with
ther KPC-2-producing strains previously identiﬁed in Brazil.3
ultilocus sequence typing (MLST) of K. pneumoniae was
erformed as described previously.14 Experimentally deter-
ined DNA sequences were uploaded into the MLST data-
ase (http://www.pasteur.fr/recherche/genopole/PF8/mlst/
pneumoniae.html), and allelic numbers and sequence types
ST) were obtained.
K. pneumoniae isolates were more frequently collected from
loodstream infections (n= 4; 57.1%) (Table 1). Amikacin,
olymyxin B, and tigecycline showed the highest suscepti-
ility rates (100%) against the isolates studied, followed by
eropenem (57.1%), imipenem (14.3%), and cefepime (14.3%).
n contrast, 100% of the isolates were resistant to ertapenem,
eftriaxone, and aztreonam. Resistance to ceftazidime, cefox-
tin, and ciproﬂoxacin was observed in six isolates (87.5%).
ll isolates showed positive MHT results and were found to
arry the blaKPC-2 gene. Two PFGE patterns, A and B, were
ound among the seven KPC-KPN; the genotype A was the
ost frequent (n= 5; 71.3%). Besides the presence of blaKPC-2,
enotype A (ST 437) isolates also carried blaTEM-1, blaOXA-1,
laCTX-M-15, and blaSHV-11, while genotype B (ST 70) carried only
laSHV-27. Using the dendrogram, a similarity of nearly 79.3%
as detected between genotype A and B. The similarity of the
PC-producing isolates evaluated in this study compared to
hose previously isolated in Recife3 was 74.5%.
For the ﬁrst time, K. pneumoniae isolates resistant to
rtapenem were detected in the Hospital Lauro Wanderley,
hich were further conﬁrmed as KPC producers. Among
he isolates studied, one (335) showed susceptibility to
eropenem and imipenem, whereas three isolates (337, 339,
nd341)were only susceptible tomeropenem, according to the
LSI breakpoints.10 The discrepancy observed in the suscepti-
le categories to carbapenemsmaybe attributed to production
f carbapenemases like KPC. The co-production of KPC with
ther beta-lactamases, such as TEM-1, OXA-1, SHV-11, SHV-27
nd CTX-M-15, was observed among KPC-KPN isolates. These
ndings are in agreement with previous Brazilian reports
hich showed that KPC-KPN isolates also possessed the
laCTX-M, blaTEM, and blaSHV genes.3,5,15 Although CTX-M-2 is a
idespread variant in South America, the isolates evaluated
arried blaCTX-M-15, a frequently foundworldwide CTX-M-type.2;16(6):577–580 579
Additionally, according to the authors’ knowledge, this is the
ﬁrst descriptionof co-productionofKPC-2 andOXA-1 inBrazil-
ian isolates. ST 437, the most prevalent among the KPC-KPN
evaluated, is a ST related to the clonal complex 258, which is
widely disseminated amongKPC-KPN inBrazil, and associated
with the dissemination of KPC worldwide.
Since the therapeutic options are limited and the appropri-
ate empirical antimicrobial treatment is of crucial importance
to patient outcome,16 we suggest that the clinical labora-
tory perform accurate susceptibility testing for KPC producers,
including the determination of MICs for tigecycline, amino-
glycosides, polymyxins, and carbapenems, since KPC-KPN
isolates with low carbapenems MICs and/or isolates with dis-
crepancy for susceptible category among carbapenems tested
were observed. In addition, regional surveillance studies
that monitor the dissemination of ESBL and carbapenemase
enzymes are crucial, since most of these genes are located
on mobile genetic elements, which are easily transferred to
other bacteria species. Because four of the ﬁve isolates were
clonally related, suggesting a patient-to-patient transmission,
implementation of infection control measures is necessary to
restrain the dissemination of resistant genes.
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